Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 189.40
Bid: 189.40
Ask: 189.80
Change: 4.80 (2.60%)
Spread: 0.40 (0.211%)
Open: 185.00
High: 192.00
Low: 185.00
Prev. Close: 184.60
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Jul 2020 07:00

RNS Number : 0566S
PureTech Health PLC
06 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Puretech Health PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: As of 1 July 2020, Merian Global Investors Limited is owned by Jupiter Fund Management Plc. Any positions in Merian Global Investors Limited are transferred to Jupiter Fund Management Plc.

The disclosure also highlights the full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity detailed within Section 9, following this change of ownership.

X

3. Details of person subject to the notification obligationiv

Name

Jupiter Fund Management Plc

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

Northern Trust

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

01/07/2020

6. Date on which issuer notified (DD/MM/YYYY):

03/07/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.53%

0%

5.53%

285,512,461

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BY2Z0H74

N/A

15,799,957

 

N/A

5.53%

SUBTOTAL 8. A

15,799,957

 

5.53%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

N/A

N/A

N/A

N/A

SUBTOTAL 8. B 1

N/A

N/A

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

N/A

N/A

N/A

N/A

N/A

N/A

SUBTOTAL 8.B.2

N/A

N/A

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Jupiter Fund Management Plc

Jupiter Fund Management Group Limited

Jupiter Asset Management Group Limited

Knightsbridge Asset Management Limited

Jupiter Investment Management Group Limited

Jupiter Asset Management Limited

5.53%

0%

5.53%

Jupiter Fund Management Plc

Merian Global Investors Limited

Merian Global Investors (Jersey) Limited

Merian Global Investors (Finance) Limited

Merian Global Investors Holdings Limited

Merian Global Investors (UK) Limited

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

Contact : Claire Rodway

 

Telephone Number : 0203 817 1441

 

Place of completion

London, UK

Date of completion

3rd July 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLRAMLTMTJMBRM
Date   Source Headline
5th Jan 202212:05 pmRNSGelesis Adds to BOD & Declared Effective by SEC
20th Dec 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
16th Dec 20217:00 amRNSPRTC Provides Recap Ahead of Catalyst-Rich 2022
8th Dec 202112:00 pmRNSPRTC Presents Data at ACNP Conference For LYT-300
7th Dec 202112:00 pmRNSPRTC's Lymphatic Platform Candidate Human Study
1st Dec 202112:10 pmRNSPRTC: Gelesis' Plenity Now Broadly Available in US
1st Dec 20217:00 amRNSTotal Voting Rights
18th Nov 202112:10 pmRNSPRTC's Gelesis Receives $30M Plenity Order from Ro
16th Nov 202112:00 pmRNSPRTC Publishes Previous LYT-100 MAD Study Results
15th Nov 202112:00 pmRNSPRTC Presents at Two Upcoming Investor Conferences
12th Nov 202112:00 pmRNSPRTC Presents Immunooncology Ph 1/2 Trial at SITC
11th Nov 202112:00 pmRNSFDA Grants PRTC's LYT-200 Orphan Drug Designation
10th Nov 20217:00 amRNSPRTC Receives $100M from Founded Entity Shares
9th Nov 202112:34 pmRNSKRTX and Zai Lab to Develop KarXT in Greater China
9th Nov 20217:00 amRNSPRTC Presents at Jefferies Healthcare Conference
1st Nov 202110:20 amRNSNew Research in Journal Nature on Gelesis Tech
1st Nov 20217:00 amRNSTotal Voting Rights
22nd Oct 20216:00 pmRNSHoldings in Company - TR-1 Correction Announcement
20th Oct 20214:35 pmRNSPrice Monitoring Extension
14th Oct 202112:01 pmRNSPRTC's Vedanta Appoints Chief Legal Officer
12th Oct 20217:00 amRNSAdditional Listing
5th Oct 20211:01 pmRNSVedanta Positive Phase 2 Data in C. Diff Infection
5th Oct 20211:00 pmRNSPRTC's Sonde Launches Mental Health Monitor
29th Sep 20211:01 pmRNSAkili/Shionogi Report Positive Ph2 Data in Japan
20th Sep 20214:02 pmRNSNew PureTech Research Published In Nature Journal
14th Sep 202112:00 pmRNSPRTC to Present at Oppenheimer Healthcare Summit
1st Sep 20217:00 amRNSTotal Voting Rights
24th Aug 20217:00 amRNSHalf-year Report
23rd Aug 202112:00 pmRNSPRTC Presents LYT-100 Ph1 PK & Tolerability at ERS
17th Aug 20211:03 pmRNSAkili Deal Furthers Digital Medicine Leadership
13th Aug 202112:00 pmRNSPRTC Appoints Industry Veteran & Physician as CMO
11th Aug 202112:00 pmRNSPRTC Receives $6.5M; Imbrium to Develop LYT-503
3rd Aug 20217:00 amRNSNotice of Results
2nd Aug 20217:00 amRNSTotal Voting Rights
23rd Jul 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
22nd Jul 20211:03 pmRNSPRTC’s Akili Releases New Features for EndeavorRx
22nd Jul 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
21st Jul 202112:03 pmRNSPureTech’s Vedanta Raises $68M Series D Financing
19th Jul 202112:02 pmRNSPRTC’s Gelesis to Become Public Via Capstar SPAC
9th Jul 202112:00 pmRNSPRTC’s Vor Announces Collaboration with Janssen
8th Jul 20212:05 pmRNSPRTC’s Sonde Announces Collaboration With Qualcomm
7th Jul 202112:00 pmRNSPRTC BeiGene LYT-200 Clinical Trial Agreement
1st Jul 20217:00 amRNSTotal Voting Rights
30th Jun 202112:00 pmRNSPRTC’s Vedanta Announces New Data from IBD Study
28th Jun 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
24th Jun 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Jun 20211:28 pmRNSKaruna Announces KarXT Results in Healthy Elderly
16th Jun 202112:00 pmRNSPureTech Acquires Alivio and Oral IL-22 Candidate
2nd Jun 20217:00 amRNSPDMR Notification RSU Vesting
1st Jun 20217:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.